AssetMark Inc
ALXN

AssetMark Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

AssetMark Inc’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-53,936
Closed -$9.91M – 1559
2021
Q2 		$9.91M Buy
+53,936
New +$9.26M 0.05% 225
2021
Q1 		– Sell
-73
Closed -$11K – 1581
2020
Q4 		$11K Sell
73
-5
-6% -$643 ﹤0.01% 917
2020
Q3 		$9K Buy
78
+1
+1% +$108 ﹤0.01% 928
2020
Q2 		$9K Sell
77
-1
-1% -$106 ﹤0.01% 880
2020
Q1 		$7K Sell
78
-25,862
-100% -$2.54M ﹤0.01% 1052
2019
Q4 		$2.81M Buy
25,940
+25,723
+11,854% +$2.75M 0.02% 298
2019
Q3 		$21K Sell
217
-152
-41% -$17.1K ﹤0.01% 879
2019
Q2 		$48K Sell
369
-502
-58% -$64.7K ﹤0.01% 707
2019
Q1 		$118K Sell
871
-106
-11% -$13.2K ﹤0.01% 543
2018
Q4 		$95K Buy
977
+469
+92% +$55.4K ﹤0.01% 571
2018
Q3 		$71K Buy
508
+1
+0.2% +$125 ﹤0.01% 668
2018
Q2 		$63K Buy
507
+16
+3% +$1.87K ﹤0.01% 673
2018
Q1 		$55K Sell
491
-7
-1% -$837 ﹤0.01% 705
2017
Q4 		$60K Buy
498
+234
+89% +$28.5K ﹤0.01% 736
2017
Q3 		$37K Sell
264
-5
-2% -$679 ﹤0.01% 772
2017
Q2 		$33K Buy
269
+13
+5% +$1.51K ﹤0.01% 785
2017
Q1 		$31K Buy
256
+14
+6% +$1.8K ﹤0.01% 766
2016
Q4 		$30K Sell
242
-99
-29% -$12.1K ﹤0.01% 764
2016
Q3 		$42K Buy
341
+107
+46% +$13.8K ﹤0.01% 665
2016
Q2 		$27K Buy
234
+77
+49% +$10.9K ﹤0.01% 776
2016
Q1 		$22K Buy
157
+56
+55% +$8.22K ﹤0.01% 746
2015
Q4 		$19K Buy
101
+93
+1,163% +$16.2K ﹤0.01% 809
2015
Q3 		$1K Buy
+8
New +$1.46K ﹤0.01% 696

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

AssetMark Inc's ALXN Position: Q3 2021 in Review

AssetMark Inc sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 53,936 shares — an estimated $9.91M sold.

AssetMark Inc first reported a position in ALXN in Q3 2015 and held it in 23 quarters. The position peaked at $9.91M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • AssetMark Inc reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • AssetMark Inc sold 53,936 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9.91M.
  • AssetMark Inc first reported a position in Alexion Pharmaceuticals in Q3 2015 and held it in 23 quarters.
  • AssetMark Inc's Alexion Pharmaceuticals position peaked at $9.91M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on AssetMark Inc's 13F filing for Q3 2021, filed 12 Nov 2021.